- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12.03. | Small molecules are 'resurgent' in orphan drug R&D: Evaluate | ||
| 12.03. | BridgeBio's muscle weakness data impress ahead of FDA filing | ||
| 12.03. | Novo Holdings sees assets shrink by a 3rd in wake of Novo Nordisk's nosediving share price | ||
| 12.03. | Regenxbio posts clean safety profile for DMD gene therapy as pivotal data loom | ||
| 11.03. | Evotec reveals sweeping 800-person layoffs, more site closures as restructuring rolls on | ||
| 11.03. | CNS Pharma wipes glioblastoma pipeline clean in strategic pivot to fresh neurology, oncology targets | ||
| 11.03. | Salspera plans $91M IPO to fund phase 3 studies of salmonella-based cancer therapy | ||
| 10.03. | Molecular glue biotech shutters after 'brutal' few years for early-stage companies | ||
| 10.03. | Lilly pledges $500M to South Korea biopharma industry, following Roche's lead | ||
| 10.03. | FDA reconsidering Capricor's snubbed DMD cell therapy after 'lifting' rejection | ||
| 10.03. | Republican senator slams FDA rare disease rebuffs, pledges to investigate recent actions: Bloomberg | ||
| 10.03. | Voyager pauses Alzheimer's program just 8 months after unveiling asset | ||
| 10.03. | Ascletis eyes quarterly GLP-1 dosing following phase 2 obesity readout | ||
| 10.03. | BioNTech's CEO, CMO prep departure to set up next-gen mRNA spinout | ||
| 10.03. | Vertex races to FDA after phase 3 kidney disease data impress analysts | ||
| 09.03. | BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3 | ||
| 09.03. | Xenon Pharmaceuticals phase 3 epilepsy readout 'blows away' expectations, stock soars | ||
| 09.03. | Tenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater China | ||
| 09.03. | AbbVie ties $350M amylin bet to almost 10% weight loss after 12 weeks | ||
| 09.03. | Pfizer ramps up plans for trispecific after phase 2 eczema win | ||
| 09.03. | Regeneron's obesity drug shows Zepbound-like efficacy in phase 3 | ||
| 09.03. | Italy's Alfasigma pens $690M deal for GSK itching drug awaiting FDA approval decision | ||
| 09.03. | Roche's oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits | ||
| 06.03. | FDA to end 9-month advisory committee drought with April review of AstraZeneca's oral SERD, Truqap | ||
| 06.03. | Beam rejigs deal to retain base editing technology amid partner's dissolution |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.